---
title: "GeneDx - CW27 | 8-K: FY2025 Revenue: USD 427 M"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/272325013.md"
datetime: "2026-01-12T22:13:18.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/272325013.md)
  - [en](https://longbridge.com/en/news/272325013.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/272325013.md)
generator: "portal-rs"
---

# GeneDx - CW27 | 8-K: FY2025 Revenue: USD 427 M

Revenue: As of FY2025, the actual value is USD 427 M.

### Financial Metrics Summary

#### Revenue and Operational Metrics

-   GeneDx Holdings Corp. reported full year 2025 revenues of $427 million, with exome and genome revenue increasing by 54% (58% excluding a one-time 2024 benefit). Fourth quarter 2025 revenues were $121 million, with a 32% increase in exome and genome revenue (43% excluding a one-time 2024 benefit).
-   Exome and genome test result volume for the full year 2025 was 97,271, marking a 30.5% year-over-year increase. The fourth quarter saw a volume of 27,761, a 34.3% increase year-over-year.
-   The adjusted gross margin for both the full year and fourth quarter of 2025 was 71%.

#### Cash Flow

-   As of December 31, 2025, GeneDx Holdings Corp. had cash, cash equivalents, marketable securities, and restricted cash totaling approximately $172 million.

#### Unique Metrics

-   The company experienced a significant increase in exome and genome test result volumes, with a 30.5% increase for the full year 2025 and a 34.3% increase in the fourth quarter.

#### Outlook / Guidance

-   For the full year 2026, GeneDx Holdings Corp. expects revenues to be between $540 and $555 million, with exome and genome revenue and volume growth anticipated to be between 33% to 35%. The adjusted gross margin is expected to be at least 70%, and the adjusted net income is projected to remain positive.

### Related Stocks

- [WGSWW.US](https://longbridge.com/en/quote/WGSWW.US.md)

## Related News & Research

- [PepsiCo Hasn't Been This Cheap Relative to Free Cash Flow in 10 Years. Here's Why That's the Signal to Buy.](https://longbridge.com/en/news/298135920.md)
- [Goldman sees $120/bbl oil risk if attacks on Middle East vessels intensify, Bloomberg reports](https://longbridge.com/en/news/298161346.md)
- [Does IMAAVY’s Approval and Ongoing Talc Verdict Meaningfully Shift the Bull Case for Johnson & Johnson (JNJ)?](https://longbridge.com/en/news/298140186.md)
- [Should Williams-Sonoma’s (WSM) Upgraded 2026 Outlook Amid Tariffs Require Action From Investors?](https://longbridge.com/en/news/298137578.md)
- [Tesla Stock And Global Auto Rivals As Buyers Shift From UK Legacy Brands](https://longbridge.com/en/news/298137549.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**